PERSPECTIVE THERAPEUTICS INC (CATX) Stock Fundamental Analysis

NYSEARCA:CATX • US46489V3024

5.17 USD
-0.18 (-3.36%)
At close: Mar 3, 2026
5.18 USD
+0.01 (+0.19%)
After Hours: 3/3/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, CATX scores 2 out of 10 in our fundamental rating. CATX was compared to 520 industry peers in the Biotechnology industry. CATX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CATX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CATX has reported negative net income.
  • In the past year CATX has reported a negative cash flow from operations.
  • CATX had negative earnings in each of the past 5 years.
  • CATX had a negative operating cash flow in each of the past 5 years.
CATX Yearly Net Income VS EBIT VS OCF VS FCFCATX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • CATX's Return On Assets of -35.89% is fine compared to the rest of the industry. CATX outperforms 60.58% of its industry peers.
  • Looking at the Return On Equity, with a value of -43.68%, CATX is in the better half of the industry, outperforming 68.08% of the companies in the same industry.
Industry RankSector Rank
ROA -35.89%
ROE -43.68%
ROIC N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
CATX Yearly ROA, ROE, ROICCATX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CATX Yearly Profit, Operating, Gross MarginsCATX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CATX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CATX has been increased compared to 5 years ago.
  • The debt/assets ratio for CATX has been reduced compared to a year ago.
CATX Yearly Shares OutstandingCATX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CATX Yearly Total Debt VS Total AssetsCATX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 5.13 indicates that CATX is not in any danger for bankruptcy at the moment.
  • CATX has a Altman-Z score of 5.13. This is in the better half of the industry: CATX outperforms 72.50% of its industry peers.
  • CATX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of CATX (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 5.13
ROIC/WACCN/A
WACC8.68%
CATX Yearly LT Debt VS Equity VS FCFCATX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 8.66 indicates that CATX has no problem at all paying its short term obligations.
  • The Current ratio of CATX (8.66) is better than 75.96% of its industry peers.
  • A Quick Ratio of 8.66 indicates that CATX has no problem at all paying its short term obligations.
  • CATX's Quick ratio of 8.66 is fine compared to the rest of the industry. CATX outperforms 75.96% of its industry peers.
Industry RankSector Rank
Current Ratio 8.66
Quick Ratio 8.66
CATX Yearly Current Assets VS Current LiabilitesCATX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CATX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.45%, which is quite impressive.
  • Looking at the last year, CATX shows a very negative growth in Revenue. The Revenue has decreased by -59.50% in the last year.
  • Measured over the past years, CATX shows a very negative growth in Revenue. The Revenue has been decreasing by -27.60% on average per year.
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-59.5%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%

3.2 Future

  • Based on estimates for the next years, CATX will show a decrease in Earnings Per Share. The EPS will decrease by -3.65% on average per year.
  • Based on estimates for the next years, CATX will show a very strong growth in Revenue. The Revenue will grow by 189.01% on average per year.
EPS Next Y-52.53%
EPS Next 2Y-26.34%
EPS Next 3Y-12.26%
EPS Next 5Y-3.65%
Revenue Next Year-20.65%
Revenue Next 2Y-14.99%
Revenue Next 3Y-19.07%
Revenue Next 5Y189.01%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CATX Yearly Revenue VS EstimatesCATX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
CATX Yearly EPS VS EstimatesCATX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CATX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CATX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATX Price Earnings VS Forward Price EarningsCATX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CATX Per share dataCATX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as CATX's earnings are expected to decrease with -12.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.34%
EPS Next 3Y-12.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CATX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (3/3/2026, 8:04:00 PM)

After market: 5.18 +0.01 (+0.19%)

5.17

-0.18 (-3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners58.75%
Inst Owner Change-15.11%
Ins Owners0.74%
Ins Owner Change0.01%
Market Cap588.91M
Revenue(TTM)1.07M
Net Income(TTM)-105.80M
Analysts82.11
Price Target12.95 (150.48%)
Short Float %9.49%
Short Ratio2.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.32%
Min EPS beat(2)-5.16%
Max EPS beat(2)5.8%
EPS beat(4)3
Avg EPS beat(4)7.22%
Min EPS beat(4)-5.16%
Max EPS beat(4)20.23%
EPS beat(8)6
Avg EPS beat(8)-8.87%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)37.81%
Min Revenue beat(2)-8.46%
Max Revenue beat(2)84.07%
Revenue beat(4)2
Avg Revenue beat(4)50.48%
Min Revenue beat(4)-8.46%
Max Revenue beat(4)132.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.12%
PT rev (3m)-3.43%
EPS NQ rev (1m)2.45%
EPS NQ rev (3m)2.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.02%
Revenue NQ rev (1m)1.66%
Revenue NQ rev (3m)-3.6%
Revenue NY rev (1m)-2.85%
Revenue NY rev (3m)-5.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 547.83
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 3.06
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0.01
BVpS2.13
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.89%
ROE -43.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 760.26%
Cap/Sales 2085.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.66
Quick Ratio 8.66
Altman-Z 5.13
F-Score1
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-52.53%
EPS Next 2Y-26.34%
EPS Next 3Y-12.26%
EPS Next 5Y-3.65%
Revenue 1Y (TTM)-59.5%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%
Revenue Next Year-20.65%
Revenue Next 2Y-14.99%
Revenue Next 3Y-19.07%
Revenue Next 5Y189.01%
EBIT growth 1Y-8.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.87%
EBIT Next 3Y-12.88%
EBIT Next 5YN/A
FCF growth 1Y-220.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.93%
OCF growth 3YN/A
OCF growth 5YN/A

PERSPECTIVE THERAPEUTICS INC / CATX FAQ

Can you provide the ChartMill fundamental rating for PERSPECTIVE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CATX.


Can you provide the valuation status for PERSPECTIVE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PERSPECTIVE THERAPEUTICS INC (CATX). This can be considered as Overvalued.


How profitable is PERSPECTIVE THERAPEUTICS INC (CATX) stock?

PERSPECTIVE THERAPEUTICS INC (CATX) has a profitability rating of 1 / 10.


How sustainable is the dividend of PERSPECTIVE THERAPEUTICS INC (CATX) stock?

The dividend rating of PERSPECTIVE THERAPEUTICS INC (CATX) is 0 / 10 and the dividend payout ratio is 0%.